Maravai LifeSciences Holdings, Inc. (MAR.F)
- GuruFocus.com
Steven Cohen's Strategic Acquisition in Maravai LifeSciences Holdings Inc
On June 7, 2024, Steven Cohen (Trades, Portfolio)'s firm made a significant addition to its investment portfolio by acquiring 6,647,015 shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI). This move has increased the firm's stake in Maravai LifeSciences to 5.00% of the total shares outstanding, reflecting a strategic position with a 0.14% portfolio weight and a trade impact of 0.11%. Steven A. Cohen, Chairman and CEO of Point72, a prominent investment advisor, has a distinguished career in the financial markets.
- Zacks
Maravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
- Business Wire
TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.
